Compositions and methods for treating ewing sarcoma
AssigneesChildren's Hospital Los Angeles, Nanovalent Pharmaceuticals, Inc.
InventorsJon O. Nagy, Timothy Triche, Hyung-Gyoo Kang, Sheetal Mitra
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for treating cancer in a subject in need thereof. The methods include using hybrid polymerized liposomal nanoparticles comprising, both polymerizable lipids and non-polymerizable lipids. The nanoparticles further comprise targeting agents and therapeutic agents.
Claims26
A method of treating, inhibiting, reducing the severity of, and/or slowing the progression of a condition in a human subject in need thereof, comprising:
- providing a hybrid polymerized liposomal nanoparticle comprising a polymerizable lipid and a non-polymerizable lipid,
- wherein the polymerizable lipid comprises at least one PEGylated polymerizable lipid having a PEG polymer chain;
- and
- wherein a therapeutic agent is loaded into the hybrid polymerized liposomal nanoparticle;
- and
- administering a therapeutically effective amount of the hybrid polymerized liposomal nanoparticle to the subject,
- wherein the therapeutic agent is an antisense oligonucleotide, wherein the antisense oligonucleotide is any one or more of FA3 having the sequence set forth in SEQ ID NO:
- 1, FA7 having the sequence set forth in SEQ ID NO:
- 2, FA8 having the sequence set forth in SEQ ID NO:3 or combinations thereof;
- thereby treating, inhibiting, reducing the severity of and/or slowing the progression of the condition in the subject.
A method of treating, inhibiting, reducing the severity of, and/or slowing the progression of Ewing sarcoma in a human subject in need thereof comprising:
- providing a hybrid polymerized liposomal nanoparticle comprising a polymerizable lipid and a non-polymerizable lipid,
- wherein the polymerizable lipid comprises at least one PEGylated polymerizable lipid having a PEG polymer chain;
- and
- wherein a therapeutic agent comprising an antisense oligonucleotide having the sequence set forth in SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3 or a combination thereof, is loaded into the hybrid polymerized liposomal nanoparticle;
- and
- administering a therapeutically effective amount of the hybrid polymerized liposomal nanoparticle to the subject, thereby treating, inhibiting, reducing the severity of and/or slowing the progression of Ewing sarcoma in the subject.
Dependencies are inferred from the claim text.